{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T13:50:15Z","timestamp":1765547415897,"version":"3.40.4"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,4,21]]},"DOI":"10.7759\/cureus.82736","type":"journal-article","created":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T23:06:21Z","timestamp":1745276781000},"source":"Crossref","is-referenced-by-count":1,"title":["Intranasal Chlorpheniramine for Early Symptomatic Treatment of COVID-19 and the Impact on Long-COVID"],"prefix":"10.7759","author":[{"given":"Gustavo","family":"Ferrer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando","family":"Valerio-Pascua","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C\u00e9sar","family":"Alas-Pineda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristhel","family":"Gait\u00e1n-Zambrano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dennis  J","family":"Pav\u00f3n-Varela","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.633680","article-title":"COVID-19: Famotidine, histamine, mast cells, and mechanisms","volume":"12","author":"Malone RW","year":"2021","unstructured":"Malone RW, Tisdall P, Fremont-Smith P, et al.. COVID-19: Famotidine, histamine, mast cells, and mechanisms. Front Pharmacol. 2021, 12:633680. 10.3389\/fphar.2021.633680","journal-title":"Front Pharmacol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2023.1202696","article-title":"Antihistamines improve cardiovascular manifestations and other symptoms of long-COVID attributed to mast cell activation","volume":"10","author":"Salvucci F","year":"2023","unstructured":"Salvucci F, Codella R, Coppola A, et al.. Antihistamines improve cardiovascular manifestations and other symptoms of long-COVID attributed to mast cell activation. Front Cardiovasc Med. 2023, 10:1202696. 10.3389\/fcvm.2023.1202696","journal-title":"Front Cardiovasc Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22115672","article-title":"Could histamine H1 receptor antagonists be used for treating COVID-19?","volume":"22","author":"Qu C","year":"2021","unstructured":"Qu C, Fuhler GM, Pan Y. Could histamine H1 receptor antagonists be used for treating COVID-19?. Int J Mol Sci. 2021, 22:10.3390\/ijms22115672","journal-title":"Int J Mol Sci"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1128\/mbio.01088-24","article-title":"The histamine receptor H1 acts as an alternative receptor for SARS-CoV-2","volume":"15","author":"Yu F","year":"2024","unstructured":"Yu F, Liu X, Ou H, et al.. The histamine receptor H1 acts as an alternative receptor for SARS-CoV-2. mBio. 2024, 15:e0108824. 10.1128\/mbio.01088-24","journal-title":"mBio"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3390\/life14020219","article-title":"The bittersweet symphony of COVID-19: associations between TAS1Rs and TAS2R38 genetic variations and COVID-19 symptoms","volume":"14","author":"Santin A","year":"2024","unstructured":"Santin A, Spedicati B, Pecori A, et al.. The bittersweet symphony of COVID-19: associations between TAS1Rs and TAS2R38 genetic variations and COVID-19 symptoms. Life (Basel). 2024, 14:10.3390\/life14020219","journal-title":"Life (Basel)"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-10747-2","article-title":"Distribution of TAS2R38 bitter taste receptor phenotype and haplotypes among COVID-19 patients","volume":"12","author":"Risso D","year":"2022","unstructured":"Risso D, Carmagnola D, Morini G, et al.. Distribution of TAS2R38 bitter taste receptor phenotype and haplotypes among COVID-19 patients. Sci Rep. 2022, 12:7381. 10.1038\/s41598-022-10747-2","journal-title":"Sci Rep"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/s00011-020-01422-1","article-title":"Histamine receptors and COVID-19","volume":"70","author":"Ennis M","year":"2021","unstructured":"Ennis M, Tiligada K. Histamine receptors and COVID-19. Inflamm Res. 2021, 70:67-75. 10.1007\/s00011-020-01422-1","journal-title":"Inflamm Res"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1096\/fj.202000502","article-title":"Existing bitter medicines for fighting 2019-nCoV-associated infectious diseases","volume":"34","author":"Li X","year":"2020","unstructured":"Li X, Zhang C, Liu L, Gu M. Existing bitter medicines for fighting 2019-nCoV-associated infectious diseases. FASEB J. 2020, 34:6008-16. 10.1096\/fj.202000502","journal-title":"FASEB J"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-024-10211-8","article-title":"Mitigating the risks of post-acute sequelae of SARS-CoV-2 infection (PASC) with intranasal chlorpheniramine: perspectives from the ACCROS studies","volume":"24","author":"Valerio-Pascua F","year":"2024","unstructured":"Valerio-Pascua F, Baires F, Sekhon AK, et al.. Mitigating the risks of post-acute sequelae of SARS-CoV-2 infection (PASC) with intranasal chlorpheniramine: perspectives from the ACCROS studies. BMC Infect Dis. 2024, 24:1348. 10.1186\/s12879-024-10211-8","journal-title":"BMC Infect Dis"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-44477-4","article-title":"Molecular mechanism of antihistamines recognition and regulation of the histamine H(1) receptor","volume":"15","author":"Wang D","year":"2024","unstructured":"Wang D, Guo Q, Wu Z, et al.. Molecular mechanism of antihistamines recognition and regulation of the histamine H(1) receptor. Nat Commun. 2024, 15:84. 10.1038\/s41467-023-44477-4","journal-title":"Nat Commun"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2023.e15772","article-title":"Antihistamines as an early treatment for Covid-19","volume":"9","author":"Mor\u00e1n Blanco JI","year":"2023","unstructured":"Mor\u00e1n Blanco JI, Alvarenga Bonilla JA, Fremont-Smith P, Villar G\u00f3mez de Las Heras K. Antihistamines as an early treatment for Covid-19. Heliyon. 2023, 9:e15772. 10.1016\/j.heliyon.2023.e15772","journal-title":"Heliyon"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.2174\/0118715230259623231111165759","article-title":"An overview of antihistamines and their properties used for treatment of different diseases","volume":"22","author":"Chaudhari R","year":"2023","unstructured":"Chaudhari R, Gosavi S, Bornare P, et al.. An overview of antihistamines and their properties used for treatment of different diseases. Antiinflamm Antiallergy Agents Med Chem. 2023, 22:220-9. 10.2174\/0118715230259623231111165759","journal-title":"Antiinflamm Antiallergy Agents Med Chem"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijporl.2017.07.045","article-title":"Expression and localization of histamine H(1), H(2), and H(3) receptors in rat olfactory epithelium","volume":"101","author":"Yu C","year":"2017","unstructured":"Yu C, Li L, Xia Q, Tang Y. Expression and localization of histamine H(1), H(2), and H(3) receptors in rat olfactory epithelium. Int J Pediatr Otorhinolaryngol. 2017, 101:102-6. 10.1016\/j.ijporl.2017.07.045","journal-title":"Int J Pediatr Otorhinolaryngol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1096\/fj.202400452R","article-title":"Molecular mechanism of bitter taste receptor agonist-mediated relaxation of airway smooth muscle","volume":"38","author":"Conaway S Jr","year":"2024","unstructured":"Conaway S Jr, Huang W, Hernandez-Lara MA, et al.. Molecular mechanism of bitter taste receptor agonist-mediated relaxation of airway smooth muscle. FASEB J. 2024, 38:e23842. 10.1096\/fj.202400452R","journal-title":"FASEB J"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsbmb.2021.105939","article-title":"7-Ketocholesterol: Effects on viral infections and hypothetical contribution in COVID-19","volume":"212","author":"Ghzaiel I","year":"2021","unstructured":"Ghzaiel I, Sassi K, Zarrouk A, et al.. 7-Ketocholesterol: Effects on viral infections and hypothetical contribution in COVID-19. J Steroid Biochem Mol Biol. 2021, 212:105939. 10.1016\/j.jsbmb.2021.105939","journal-title":"J Steroid Biochem Mol Biol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.14639\/0392-100X-N1584","article-title":"COVID-19 manifestation in the oral cavity - a narrative literature review","volume":"41","author":"Kusiak A","year":"2021","unstructured":"Kusiak A, Cicho\u0144ska D, Tubaja M, et al.. COVID-19 manifestation in the oral cavity - a narrative literature review. Acta Otorhinolaryngol Ital. 2021, 41:395-400. 10.14639\/0392-100X-N1584","journal-title":"Acta Otorhinolaryngol Ital"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1128\/mbio.03436-21","article-title":"Human nasal epithelial cells sustain persistent SARS-CoV-2 infection in vitro, despite eliciting a prolonged antiviral response","volume":"13","author":"Gamage AM","year":"2022","unstructured":"Gamage AM, Tan KS, Chan WO, et al.. Human nasal epithelial cells sustain persistent SARS-CoV-2 infection in vitro, despite eliciting a prolonged antiviral response. mBio. 2022, 13:e0343621. 10.1128\/mbio.03436-21","journal-title":"mBio"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01873","article-title":"The role of histamine and histamine receptors in mast cell-mediated allergy and inflammation: the hunt for new therapeutic targets","volume":"9","author":"Thangam EB","year":"2018","unstructured":"Thangam EB, Jemima EA, Singh H, et al.. The role of histamine and histamine receptors in mast cell-mediated allergy and inflammation: the hunt for new therapeutic targets. Front Immunol. 2018, 9:1873. 10.3389\/fimmu.2018.01873","journal-title":"Front Immunol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2020.153296","article-title":"Phillyrin (KD-1) exerts anti-viral and anti-inflammatory activities against novel coronavirus (SARS-CoV-2) and human coronavirus 229E (HCoV-229E) by suppressing the nuclear factor kappa B (NF-\u03baB) signaling pathway","volume":"78","author":"Ma Q","year":"2020","unstructured":"Ma Q, Li R, Pan W, et al.. Phillyrin (KD-1) exerts anti-viral and anti-inflammatory activities against novel coronavirus (SARS-CoV-2) and human coronavirus 229E (HCoV-229E) by suppressing the nuclear factor kappa B (NF-\u03baB) signaling pathway. Phytomedicine. 2020, 78:153296. 10.1016\/j.phymed.2020.153296","journal-title":"Phytomedicine"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2222.2008.02990.x","article-title":"Histamine H1-receptor antagonists inhibit nuclear factor-kappaB and activator protein-1 activities via H1-receptor-dependent and -independent mechanisms","volume":"38","author":"Roumestan C","year":"2008","unstructured":"Roumestan C, Henriquet C, Gougat C, et al.. Histamine H1-receptor antagonists inhibit nuclear factor-kappaB and activator protein-1 activities via H1-receptor-dependent and -independent mechanisms. Clin Exp Allergy. 2008, 38:947-56. 10.1111\/j.1365-2222.2008.02990.x","journal-title":"Clin Exp Allergy"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2021.173897","article-title":"Repositioning of histamine H(1) receptor antagonist: Doxepin inhibits viropexis of SARS-CoV-2 Spike pseudovirus by blocking ACE2","volume":"896","author":"Ge S","year":"2021","unstructured":"Ge S, Wang X, Hou Y, et al.. Repositioning of histamine H(1) receptor antagonist: Doxepin inhibits viropexis of SARS-CoV-2 Spike pseudovirus by blocking ACE2. Eur J Pharmacol. 2021, 896:173897. 10.1016\/j.ejphar.2021.173897","journal-title":"Eur J Pharmacol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.pupt.2020.101942","article-title":"Dual-histamine receptor blockade with cetirizine - famotidine reduces pulmonary symptoms in COVID-19 patients","volume":"63","author":"Hogan Ii RB","year":"2020","unstructured":"Hogan Ii RB, Hogan Iii RB, Cannon T, et al.. Dual-histamine receptor blockade with cetirizine - famotidine reduces pulmonary symptoms in COVID-19 patients. Pulm Pharmacol Ther. 2020, 63:101942. 10.1016\/j.pupt.2020.101942","journal-title":"Pulm Pharmacol Ther"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.20980","article-title":"Molecular modeling and preliminary clinical data suggesting antiviral activity for chlorpheniramine (chlorphenamine) against COVID-19","volume":"14","author":"Black SD","year":"2022","unstructured":"Black SD. Molecular modeling and preliminary clinical data suggesting antiviral activity for chlorpheniramine (chlorphenamine) against COVID-19. Cureus. 2022, 14:e20980. 10.7759\/cureus.20980","journal-title":"Cureus"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.2174\/2772432817666220601162006","article-title":"Chlorpheniramine, an old drug with new potential clinical applications: a comprehensive review of the literature","volume":"19","author":"Rizvi SA","year":"2024","unstructured":"Rizvi SA, Ferrer G, Khawaja UA, Sanchez-Gonzalez MA. Chlorpheniramine, an old drug with new potential clinical applications: a comprehensive review of the literature. Curr Rev Clin Exp Pharmacol. 2024, 19:137-45. 10.2174\/2772432817666220601162006","journal-title":"Curr Rev Clin Exp Pharmacol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.18502\/ajmb.v15i2.12022","article-title":"Human T2R38 bitter taste receptor expression and COVID- 19: from immunity to prognosis","volume":"15","author":"Bethineedi LD","year":"2023","unstructured":"Bethineedi LD, Baghsheikhi H, Soltani A, et al.. Human T2R38 bitter taste receptor expression and COVID- 19: from immunity to prognosis. Avicenna J Med Biotechnol. 2023, 15:118-23. 10.18502\/ajmb.v15i2.12022","journal-title":"Avicenna J Med Biotechnol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1080\/07391102.2023.2300128","article-title":"Bitter taste receptors establish a stable binding affinity with the SARS-CoV-2-spike 1 protein akin to ACE2","volume":"43","author":"Kumar SA","year":"2025","unstructured":"Kumar SA, Selvaa Kumar C, Dsouza N. Bitter taste receptors establish a stable binding affinity with the SARS-CoV-2-spike 1 protein akin to ACE2. J Biomol Struct Dyn. 2025, 43:3845-58. 10.1080\/07391102.2023.2300128","journal-title":"J Biomol Struct Dyn"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1691\/ph.2021.0840","article-title":"A hypothesis: Bitter taste receptors as a therapeutic target for the clinical symptoms of SARS-CoV-2","volume":"76","author":"Kumar SA","year":"2021","unstructured":"Kumar SA, Cheng W. A hypothesis: Bitter taste receptors as a therapeutic target for the clinical symptoms of SARS-CoV-2. Pharmazie. 2021, 76:43-54. 10.1691\/ph.2021.0840","journal-title":"Pharmazie"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1002\/alr.22692","article-title":"Does phenotypic expression of bitter taste receptor T2R38 show association with COVID-19 severity?","volume":"10","author":"Barham HP","year":"2020","unstructured":"Barham HP, Taha MA, Hall CA. Does phenotypic expression of bitter taste receptor T2R38 show association with COVID-19 severity?. Int Forum Allergy Rhinol. 2020, 10:1255-7. 10.1002\/alr.22692","journal-title":"Int Forum Allergy Rhinol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.2139\/ssrn.4603627","article-title":"Chlorpheniramine maleate displays multiple modes of antiviral action against SARS-CoV-2: a mechanistic study","author":"Elshaier Y","year":"2023","unstructured":"Elshaier Y, Mostafa A, Valerio-Pascua F, et al.. Chlorpheniramine maleate displays multiple modes of antiviral action against SARS-CoV-2: a mechanistic study. bioRxiv. 2023, 10.2139\/ssrn.4603627","journal-title":"bioRxiv"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10. 10.18103\/mra.v10i3.2752","article-title":"Intranasal chlorpheniramine maleate for the treatment of COVID- 19: translational and clinical evidence","author":"Sanchez-Gonzalez M","year":"2022","unstructured":"Sanchez-Gonzalez M, Westover J, Rizvi S, et al.. Intranasal chlorpheniramine maleate for the treatment of COVID- 19: translational and clinical evidence. Med Res Arch. 2022, 10. 10.18103\/mra.v10i3.2752","journal-title":"Med Res Arch"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.21203\/rs.3.rs-2167465\/v1","article-title":"Chlorpheniramine intranasal spray to accelerate COVID-19 clinical recovery in an outpatient setting: The ACCROS trials","author":"Valerio-Pascua F","year":"2022","unstructured":"Valerio-Pascua F, Mejia EJP, Tesch ML, et al.. Chlorpheniramine intranasal spray to accelerate COVID-19 clinical recovery in an outpatient setting: The ACCROS trials. Res Squ. 2022, 10.21203\/rs.3.rs-2167465\/v1","journal-title":"Res Squ"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.10501","article-title":"In vitro virucidal effect of intranasally delivered chlorpheniramine maleate compound against severe acute respiratory syndrome coronavirus 2","volume":"12","author":"Westover JB","year":"2020","unstructured":"Westover JB, Ferrer G, Vazquez H, et al.. In vitro virucidal effect of intranasally delivered chlorpheniramine maleate compound against severe acute respiratory syndrome coronavirus 2. Cureus. 2020, 12:e10501. 10.7759\/cureus.10501","journal-title":"Cureus"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/350279-intranasal-chlorpheniramine-for-early-symptomatic-treatment-of-covid-19-and-the-impact-on-long-covid","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T23:06:22Z","timestamp":1745276782000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/350279-intranasal-chlorpheniramine-for-early-symptomatic-treatment-of-covid-19-and-the-impact-on-long-covid"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,21]]},"references-count":32,"URL":"https:\/\/doi.org\/10.7759\/cureus.82736","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4,21]]}}}